BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21225914)

  • 1. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
    Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
    Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate.
    Rakheja D; Boriack RL; Mitui M; Khokhar S; Holt SA; Kapur P
    Tumour Biol; 2011 Apr; 32(2):325-33. PubMed ID: 21080253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.
    Kranendijk M; Struys EA; van Schaftingen E; Gibson KM; Kanhai WA; van der Knaap MS; Amiel J; Buist NR; Das AM; de Klerk JB; Feigenbaum AS; Grange DK; Hofstede FC; Holme E; Kirk EP; Korman SH; Morava E; Morris A; Smeitink J; Sukhai RN; Vallance H; Jakobs C; Salomons GS
    Science; 2010 Oct; 330(6002):336. PubMed ID: 20847235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
    Reitman ZJ; Yan H
    J Natl Cancer Inst; 2010 Jul; 102(13):932-41. PubMed ID: 20513808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
    Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
    Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
    Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
    Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.
    Matsunaga H; Futakuchi-Tsuchida A; Takahashi M; Ishikawa T; Tsuji M; Ando O
    Biochem Biophys Res Commun; 2012 Jul; 423(3):553-6. PubMed ID: 22683334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel cases of D-2-hydroxyglutaric aciduria with IDH1 or IDH2 mosaic mutations identified by amplicon deep sequencing.
    Nota B; Hamilton EM; Sie D; Ozturk S; van Dooren SJ; Ojeda MR; Jakobs C; Christensen E; Kirk EP; Sykut-Cegielska J; Lund AM; van der Knaap MS; Salomons GS
    J Med Genet; 2013 Nov; 50(11):754-9. PubMed ID: 24049096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
    Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
    Mascelli S; Raso A; Biassoni R; Severino M; Sak K; Joost K; Milanaccio C; Barra S; Grillo-Ruggieri F; Vanni I; Consales A; Cama A; Capra V; Nozza P; Garrè ML
    J Neurooncol; 2012 Sep; 109(3):477-84. PubMed ID: 22821382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
    Krell D; Assoku M; Galloway M; Mulholland P; Tomlinson I; Bardella C
    PLoS One; 2011; 6(5):e19868. PubMed ID: 21625441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.